Spots Global Cancer Trial Database for follicular
Every month we try and update this database with for follicular cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim | NCT04947618 | Lymphoma, Malig... | 15 Years - | Centre Hospitalier Universitaire de Nīmes | ||
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | NCT01121757 | Follicular Lymp... Marginal Zone L... | azacitidine lenalidomide | 18 Years - | Duke University | |
| Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | NCT00168740 | Low-Grade or Fo... | rituximab | 18 Years - | Biogen | |
| Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | NCT00537095 | Thyroid Neoplas... | Vandetanib Placebo | 18 Years - | Sanofi | |
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | NCT06070961 | Follicular Lymp... | Cellular immuni... Humoral immunit... Cellular immuni... Humoral immunit... Diphtheria toxi... Tetanus toxoid-... T-cell populati... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) | NCT04618081 | Lymphoma Nonhod... | 18 Years - | Celgene | ||
| A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | NCT00452127 | Non-Hodgkin's L... | PRO131921 | 18 Years - | Genentech, Inc. | |
| Primary Rituximab and Maintenance | NCT00140582 | Follicular Lymp... | Rituximab | 18 Years - | Lymphoma Study Association | |
| Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) | NCT00168740 | Low-Grade or Fo... | rituximab | 18 Years - | Biogen | |
| Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | NCT00984282 | Thyroid Neoplas... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | NCT02956382 | Refractory Foll... Relapsed Follic... | Ibrutinib Venetoclax | 18 Years - | Georgetown University | |
| "MIRO" Molecularly Oriented Immuno-radio-therapy | NCT02710643 | Follicular Lymp... Follicular Lymp... Follicular Lymp... | OFATUMUMAB | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | NCT00537095 | Thyroid Neoplas... | Vandetanib Placebo | 18 Years - | Sanofi | |
| REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas | NCT00287287 | Thyroid Neoplas... | Lenalidomide | 18 Years - | University of Kentucky | |
| "MIRO" Molecularly Oriented Immuno-radio-therapy | NCT02710643 | Follicular Lymp... Follicular Lymp... Follicular Lymp... | OFATUMUMAB | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma | NCT00582270 | Indolent Non-Ho... | 18 Years - | Memorial Sloan Kettering Cancer Center | ||
| Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | NCT00384150 | Lymphoma, Non-H... | galiximab in co... | 18 Years - | Biogen | |
| Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma | NCT00091676 | Non-Hodgkins Ly... | FNHLId1 KLH + GM-CSF | 18 Years - | Biovest International | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | NCT01059630 | Non-Hodgkin's L... | Obinutuzumab Bendamustine | 18 Years - | Genentech, Inc. | |
| REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas | NCT00287287 | Thyroid Neoplas... | Lenalidomide | 18 Years - | University of Kentucky | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | NCT00384150 | Lymphoma, Non-H... | galiximab in co... | 18 Years - | Biogen | |
| Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) | NCT04618081 | Lymphoma Nonhod... | 18 Years - | Celgene | ||
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma | NCT00078598 | Non-Hodgkin's L... | Rituximab or Io... | 18 Years - | Corixa Corporation | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
